The association between the diversity of the oral microbiome and PFS
Multiple Myeloma Hub - A podcast by Scientific Education Support
![](https://is2-ssl.mzstatic.com/image/thumb/Podcasts115/v4/3c/dc/5e/3cdc5e39-bfb4-cbdd-8064-a6b4e7840a90/mza_11835610604067903273.jpeg/300x300bb-75.jpg)
Categories:
During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub spoke to Steering Committee Member Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, AT. This podcast outlines a study that aimed to determine the impact of the oral microbiome in patients uniformly treated with ixazomib + thalidomide + dexamethasone combination therapy for the treatment of relapsed/refractory MM.
Oral microbiome characteristics are highly heterogeneous between patients, and a higher microbiome diversity has been associated with favorable prognosis in patients with cancer. However, there remains a lack of data surrounding the influence of the oral microbiome on survival outcomes in patients with MM. This study sought to provide answers—listen for more information!
See acast.com/privacy for privacy and opt-out information.